On April 10, ASCO launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes. The registry will collect both baseline and follow-up data throughout the COVID-19 pandemic and into 2021.
“The cancer care community needs data on how the virus is impacting our patients, their cancer treatment, and outcomes to inform current cancer care and decision-making for future disease outbreaks. We encourage all oncology practices to participate so that we can learn from every patient, in every practice, in every state across the country.”— Howard “Skip” Burris III, MD, FACP, FASCO
Tweet this quote
“As this unprecedented public health crisis continues, we’re seeing that certain populations—including individuals with cancer—are more likely to be vulnerable to the worst outcomes from COVID-19,” said ASCO President Howard “Skip” Burris III, MD, FACP, FASCO. “The cancer care community needs data on how the virus is impacting our patients, their cancer treatment, and outcomes to inform current cancer care and decision-making for future disease outbreaks. We encourage all oncology practices to participate so that we can learn from every patient, in every practice, in every state across the country.”
Once sufficient patient data have been received and analyzed, ASCO will deliver periodic reports to the cancer community and the broader public on key learnings, such as characteristics of patients with cancer most impacted by COVID-19, estimates of disease severity, treatment modifications or delays, implementation of telemedicine in the cancer treatment setting, and clinical outcomes among patients related to both COVID-19 and cancer. ASCO also plans to develop peer-reviewed manuscripts based on the data provided.
The ASCO Registry is designed to capture not just point-in-time data on patients with cancer, but longitudinal data on how the virus impacts care and outcomes during the COVID-19 pandemic and into 2021.
“By looking at longitudinal data on patients, we’ll be able to learn more about the longer-term of effects of COVID-19 and its impact on cancer care,” explained Dr. Burris. “We hope to learn if the virus resulted in specific complications for patients, delayed patients’ ability to get a specific type of treatment, or if certain approaches resulted in better outcomes for patients.”
Participating practices will be asked to complete a baseline data capture form on each patient with cancer who has a confirmed diagnosis of COVID-19 and subsequent follow-up information on status, treatment, and outcomes. Limited patient-identifying data—including zip code, date of birth, sex, race, ethnicity, type of cancer, and comorbidities—will be collected in a secure way to make longitudinal analysis possible.
Data from practices participating in the registry will be collected and securely stored on the CancerLinQ platform. Additionally, CancerLinQ will be capturing data directly from CancerLinQ-participating practices on COVID-19 infection in their patients with cancer to allow for future analyses. The ASCO Registry uses several data elements that are included in ASCO's mCODE.
Eleven practices have already expressed interested in participating in the ASCO Registry:
The Web-based registry is open to all U.S. oncology practices and will collect data from patients with all types of cancer who are undergoing all types of cancer treatment. All participating practices will receive nominal financial support to cover research data-entry costs. The funding is supported by Conquer Cancer, The ASCO Foundation.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.